Ask My Investor AI
Public company · NasdaqPublished company research
DXCM

Identity verified against DexCom, Inc.'s Q1 2026 Form 10-Q, CIK 0001093557.

DexCom, Inc.

DexCom is a focused continuous glucose monitoring company. Q1 2026 revenue was $1,191.9 million, up 15% reported, with U.S. revenue of $832.3 million and international revenue of $359.6 million. The company also reported positive CONNECT trial results for adults with type 2 diabetes not using insulin.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
DXCM
Exchange
Nasdaq
HQ
United States
Currency
USD
SEC CIK
0001093557
Investment case

How this company captures the theme economics

Competitive position

Official sources establish a current CGM product franchise, double-digit Q1 growth and clinical evidence in a broader adult type 2 population. This bounded review does not rely on third-party market-share estimates or predict reimbursement expansion.

Scarce assets

The relevant assets are Dexcom's CGM sensor platform, regulatory clearances, manufacturing capacity, data connectivity and clinical evidence. Their economic durability is an analytical question that remains subject to human review.

Products, segments, and customers

DexCom develops and commercializes continuous glucose monitoring systems. It reports revenue by U.S. and international geography rather than by customer age or Aging in Place use case.

Theme capture

CGM can support chronic-disease monitoring outside clinical settings. The CONNECT trial showed benefits in adults with type 2 diabetes not using insulin regardless of age, but that evidence is not aging-specific and does not establish a Medicare coverage change.

Conditions

What must be true

  1. CGM adoption and reimbursement continue to broaden without unacceptable pricing or margin pressure.
  2. An evidence-based method establishes how much of DexCom's business is attributable to older adults or aging at home before theme materiality is accepted.

Identifiable catalysts

  • Publication and external evaluation of the CONNECT randomized trial
  • Further official reimbursement or coverage decisions, if issued
  • Continued U.S. and international CGM adoption
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Continuous glucose monitoring that can support chronic-disease management outside clinical settings.

Aging-in-place economy

DexCom reported Q1 2026 revenue of $1,191.9 million, including $832.3 million in the United States and $359.6 million internationally. Its CONNECT trial reported improved glucose-control outcomes in adults with type 2 diabetes not using insulin regardless of age. Neither source quantifies older-adult revenue or establishes the previously predicted Medicare coverage expansion.

Evidence
The SEC filing directly supports current financial results; the issuer trial release supports the reported study population and outcomes. Policy expansion and aging-specific materiality remain unsupported and are excluded.
Materiality
estimated — CGM is relevant to independent chronic-disease management, but DexCom does not disclose age-segmented or Aging in Place revenue.
Financial evidence

Official SEC filing evidence

Reference period: Q1 2026.

  • Total revenue$1,191.9 million
    Q1 2026[1]
  • U.S. revenue$832.3 million
    Q1 2026[1]
  • International revenue$359.6 million
    Q1 2026[1]
  • Gross profit and margin$750.3 million; 62.9%
    Q1 2026[1]
  • Operating income and margin$255.3 million; 21.4%
    Q1 2026[1]
  • Net income and diluted EPS$199.5 million; $0.51
    Q1 2026[1]

Limitation: The filing does not segment revenue by age, payer or Aging in Place use. Licensed market valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • Competition, reimbursement or pricing changes slow CGM adoption or compress margins.
  • Manufacturing, product-quality or regulatory issues disrupt supply or adoption.
  • Clinical evidence in a broad adult population does not translate into coverage or financially material demand.

Thesis-break conditions

  • Revenue growth and operating performance deteriorate for multiple reporting periods.
  • Official evidence does not support a material link between DexCom and independent at-home management among older adults.
Investability conclusion

Where the evidence lands

DexCom has current filing-backed CGM growth and official adult type 2 clinical evidence, but Aging in Place attribution, reimbursement expansion and valuation are unresolved. The subject remains NOT_READY pending human review.

Next diligence

  1. Review the peer-reviewed CONNECT publication and any official coverage decision when available.
  2. Quantify payer and age exposure only from acceptable primary evidence.
  3. Obtain licensed market data and independent human review.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. DexCom, Inc. Q1 2026 Form 10-QU.S. Securities and Exchange Commission (EDGAR) · primary · published 2026-04-30 · accessed 2026-07-29
  2. Dexcom CONNECT Study resultsDexCom, Inc. · primary · published 2026-06-06 · accessed 2026-07-29